Wedge Capital Management L L P NC Sells 3,137 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wedge Capital Management L L P NC trimmed its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 239,868 shares of the specialty pharmaceutical company's stock after selling 3,137 shares during the period. Wedge Capital Management L L P NC owned 0.39% of Jazz Pharmaceuticals worth $29,780,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. Quadrant Capital Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares in the last quarter. Elequin Capital LP increased its holdings in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $28,000. Finally, Allianz SE bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $29,000. Institutional investors own 89.14% of the company's stock.

Insider Activity

In other news, Director Seamus Mulligan purchased 1,621 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company's stock, valued at approximately $10,466,963. The trade was a 1.62% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer now owns 439,307 shares in the company, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,000 shares of company stock valued at $355,925 in the last quarter. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Down 2.2%

JAZZ traded down $2.50 during trading hours on Wednesday, hitting $110.50. 847,163 shares of the company's stock were exchanged, compared to its average volume of 834,232. The stock has a market cap of $6.81 billion, a price-to-earnings ratio of 15.56, a PEG ratio of 1.04 and a beta of 0.33. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The stock's 50-day moving average is $107.65 and its two-hundred day moving average is $120.82. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter in the prior year, the company earned $2.68 EPS. The company's revenue for the quarter was down .5% on a year-over-year basis. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. Royal Bank of Canada cut their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.